Global Partners LP (GLP)

GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution

Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Zacks Industry Outlook Western Midstream, Global Partners and NGL Energy Partners

Refining & Marketing MLP Industry Shines: 3 Stocks to Watch

Eli Lilly: Buy The GLP-1 Growth Premium

FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body

Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?

GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

Critical Analysis: Global Partners (NYSE:GLP) and EQT (NYSE:EQT)

MichaelAaron Flicker on How GLP-1s Change Food Industry & Household Dynamics

36,399 Shares of Global Partners LP $GLP Bought by Bank of America Corp DE

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

Should Value Investors Buy Global Partners (GLP) Stock?

Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study

Solvonis says alcohol treatment outpaces GLP-1 drugs in cross-trial comparison

Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s